Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Tryptamines”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources

N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor.

Previous studies indicated that selected ergolines and tryptamines showed species differences for affinity to the antagonist-labeled 5-HT2 receptor. The present study examined these same compounds for affinity at the agonist-labeled 5-HT2 receptor in rat and squirrel monkey cortical homogenates using [125I]DOI ([125I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane). As seen with the antagonist-labeled 5-HT2 receptor, N(1) alkyl substitution of either the ergolines or tryptamines resulted in a slight increase or no effect on their affinity for the agonist-labeled rat 5-HT2 receptor. In contrast, these same N(1) substitutions resulted in significant decreases in affinity for the agonist-labeled monkey 5-HT2 receptor. It was also noted that N(1)-unsubstituted ergolines and tryptamines (such as ergonovine, LY86057, LY193525 and 5-methoxytryptamine) tended to have higher affinity for the monkey versus the rat agonist-labeled receptor. However, the N(1) alkyl-substituted ergolines and tryptamines (such as mesulergine, LY53857, amesergide, N(1)-isopropyltryptamine and N(1)-isopropyl-5-methoxytryptamine) showed significantly lower affinity for the monkey versus the rat 5-HT2 receptor. These data suggest that, at least in relation to the N(1) position, ergolines and tryptamines bind in a similar orientation. These results are also discussed in terms of what amino acid differences between species may account for this structure-activity relationship.

Amphetamines↗

The involvement of insulin in tryptamine-induced hypoglycemia in mice.

The effects of tryptamine on plasma glucose and serum insulin levels were studied in mice. Tryptamine elicited dose-dependent hypoglycemia and hyperinsulinemia in intact mice. In streptozotocin-diabetic mice, tryptamine did not change plasma glucose nor serum insulin levels. Tryptamine significantly inhibited glucose-induced hyperglycemia and enhanced insulin release elicited by glucose. These results indicate that tryptamine-induced hypoglycemia is brought on by its releasing effects of insulin.

Animals↗

Strain differences in the behaviour induced by tryptamine in five strains of mice.

The effect of intravenous tryptamine on behaviour was investigated in five strains of mice. Tryptamine at 25 mg/kg induced head weaving and hindlimb abduction in all strains of mice. The intensity of these responses correlated significantly with the content of brain tryptamine. Tryptamine also elicited head twitch and this response was unrelated to the content of brain tryptamine.

Animals↗

X-ray crystallographic and molecular orbital studies on the conformation of tryptamine.

The crystal structure of neutral tryptamine has been determined by X-ray methods. The refinements result in a conventional R value of 0.043. Tryptamine molecules are held together to form layered structures perpendicular to the c axis by van der Waals contacts and by N-H...N type hydrogen bonds. The conformation is similar to that of other cationic tryptamines. By the conformational energy calculation which was carried out by the Complete Neglect of Differential Overlap (CNDO/2) method, it is shown that the folded conformation observed in this crystal structure is attributed mainly to the nature of tryptamine molecule. Furthermore, it seems likely that this conformation is also significant and common in other numerous unsubstituted indolealkylamines, because their conformations are similar to that of the tryptamine.

Models, Molecular↗

Human tryptamine metabolism decreases during night sleep.

Fourteen healthy male volunteers took part in a study which aimed to determine whether utilization of tryptamine changes in relation to sleep and wakefulness. For this purpose urine samples were collected every 4 hr and urinary tryptamine and indoleacetic acid (IAA) were determined by fluorometric and spectrophotometric methods. Urinary concentration of IAA progressively increased during the day and fell during the night when subjects were asleep but not when subjects were awake. This evidence indicates that behavioral state rather than circadian variation determines the level of urinary IAA. Tryptamine (T) concentration also progressively increased during the day and continued to increase during the night. The mean log10 (IAA/T) ratio indicates that tryptamine metabolism decreases during the night when subjects are asleep. Therefore, human sleep may be associated with diminished activity of peripheral tryptamine.

Adult↗

Tryptamine receptors: fact, myth or misunderstanding?

Tryptamine is an endogenous brain amine which is implicated in neural regulation and proposed to play a significant role in the aetiology of some neuropsychiatric illnesses. Recent reports indicate the possible existence of specific tryptamine binding sites. It has been postulated that these binding sites may be functional tryptamine receptors in the central nervous system. The status of current developments in this area is critically reviewed. Current problems are outlined and discussed in terms of the specificity of the [3H]-tryptamine binding site and its functional assessment with experiments involving both drug treatment and electrolytic and neurotoxin-induced brain lesions. Current data indicate that the [3H]-tryptamine binding site is selective and not attributable to residual monoamine oxidase binding.

Animals↗

A high-affinity [3H]tryptamine binding site in human brain.

In vitro filtration binding revealed high-affinity specific [3H]tryptamine binding sites in human brain. These binding sites are heterogeneously distributed throughout brain, ranging from 280 fmol/mg protein in hippocampus and thalamus to approximately 90 fmol/mg protein in medulla oblongata and cerebellum. Preliminary autoradiographic studies indicate a heterogeneous distribution within layers of the frontal cortex. The observed stereoselectivity of the site, the interaction of the site with a G protein and the observed region-selective downregulation of the site in a human pathological condition, i.e. hepatic encephalopathy (Mousseau et al., 1994), suggests that this binding site is a functional [3H]tryptamine receptor. A similarity in kinetics and distribution of the [3H]tryptamine receptor in human and rat brain indicates that these two entities represent homologous structures, although the difference in pharmacological profiles suggests species variants. One cannot exclude the possibility that the rat and human [3H]tryptamine receptors do represent distinct subtypes. Finally, the suggested role for tryptamine in neuropsychiatric disorders as originally suggested by Dewhurst (1968) is supported by the present series of experiments.

Aged↗

5-(Sulfonyl)oxy-tryptamines and ethylamino side chain restricted derivatives. Structure-affinity relationships for h5-HT1B and h5-HT1D receptors.

A number of sulfonic acid ester derivatives of serotonin (5-hydroxytryptamine; 5-HT; 1) were prepared and their affinities are compared to that of the reference compound 5-[[(trifluoromethyl)sulfonyl]oxy]-tryptamine (8b). The structure-affinity relationship (SAFIR) is discussed in terms of in vitro binding for cloned human h5-HT1A, h5-HT1B and h5-HT1D receptors. All tryptamine derivatives exhibited the best affinities for h5-HT1D receptors but still, these were comparatively lower than that of compound 8b. 5-Tosylated tryptamine 11b (Ki = 6 nM) and the sulfamate derivatives 13b and 14b (Ki = 7 and 11 nM, respectively) were found to have the highest affinities for the h5-HT1D receptor. Other tryptamine derivatives displayed moderate binding for h5-HT1A and h5-HT1B receptors, along with Ki values ranging from 14-20 nM for the h5-HT1D sites. In addition, the syntheses of two alkylamino side chain restricted derivatives are described. 3-Amino-6-[[(trifluoromethyl)sulfonyl]oxy]-1,2,3,4-tetrahydrocarbazol e 21, as well as 4-[5-[[(trifluoromethyl)sulfonyl]oxy]-1H-indol-3-yl]piperidines 24 and 25, induced a shift in selectivity in favor of the h5-HT1B receptor. The relatively longer distance between the basic amine and a hydrogen-bond accepting oxygen in 21, 24 and 25 as compared to the non-restricted tryptamines, is likely responsible for this observation.

Animals↗

Application of tryptamine as a derivatising agent for airborne isocyanate determination. Part 3. Evaluation of total isocyanates analysis by high-performance liquid chromatography with fluorescence and amperometric detection.

Determination of total airborne isocyanates using tryptamine as the derivatising agent was investigated. Tryptamine derivatised isocyanates were analysed by reversed-phase high-performance liquid chromatography (HPLC). The column was equipped with dual detectors of fluorescence emission and amperometric oxidation. The characteristics of fluorescence emission and amperometric oxidation of tryptamine were retained even after its reaction with isocyanates. With this unique behaviour, all tryptamine derivatised isocyanates can be quantified using HPLC by employing a single, pure derivative, such as tryptamine derivatised hexamethylene diisocyanate as the calibration standard. This is especially important for analysing polymeric isocyanates when identical calibration standards are not always available. The applicability of this method for air sampling was evaluated by comparison with the established method of Bagon et al. involving 1-(2-methoxyphenyl)piperazine. Simulation of air sampling was performed in a Test Atmosphere Generation System by the vaporisation of toluene diisocyanate. Satisfactory results were obtained, indicating the applicability of this technique for the determination of total airborne isocyanates.

Air Pollutants, Occupational↗

Electronically excited states of tryptamine and its microhydrated complex.

The lowest electronically excited singlet states of tryptamine and the tryptamine (H2O)1 cluster have been studied, using time dependent density functional theory for determination of the geometries and multireference configuration interaction for the vertical and adiabatic excitation energies, the permanent dipole moments, and the transition dipole moment orientations. All molecular properties of the seven experimentally observed conformers of tryptamine could be reproduced with high accuracy. A strong solvent reorientation has been found upon electronic excitation of the 1:1 water cluster of tryptamine to the L(a) and L(b) states. The adiabatically lowest excited singlet state in case of the tryptamine monomer is the L(b) state, while for the 1:1 water complex, the L(a) is calculated below the L(b) state.

Computer Simulation↗

Effect of intranigral administration of 6-hydroxydopamine and 5,7-dihydroxytryptamine on rat brain tryptamine.

Earlier experiments have shown that unilateral electrolytic lesions of the substantia nigra result in significant reductions in the rate of accumulation of rat striatal tryptamine. For elucidation of the type of neuronal degeneration that is associated with tryptamine depletion, the effects of intranigral injections of 6-hydroxydopamine or 5,7-dihydroxytryptamine, which would affect, respectively, dopamine- or indoleamine-containing neurons, have been assessed. Nigral 6-hydroxydopamine lesions resulted in an ipsilateral reduction in the rate of accumulation of striatal tryptamine, but no changes were observed after nigral injections of 5,7-dihydroxytryptamine. The present results suggest that decreases in the pargyline-induced accumulation of striatal tryptamine may be associated with lesions of the nigral dopamine-containing cell bodies. Alternatively, there may exist specific tryptamine-containing neurons that are damaged by 6-hydroxytryptamine and unaffected by 5,7-dihydroxytryptamine.

5,7-Dihydroxytryptamine↗

Relative activity of some inhibitors of mono-amine oxidase in potentiating the action of tryptamine in vitro and in vivo.

Several known inhibitors of mono-amine oxidase (iproniazid, isocarboxazid, nialamide, phenelzine, pheniprazine and tranylcypromine) were tested for their ability to (i) inhibit the mono-amine oxidase activity of a rat brain mitochondrial preparation in vitro; (ii) potentiate the action of tryptamine on the isolated rat fundal strip preparation; and (iii) potentiate the acute toxicity of tryptamine in mice. There was some correlation between the order of potency of the drugs in the three tests, particularly in inhibiting the enzyme activity in the Warburg and in the tryptamine toxicity test in mice. Exceptions to this were isocarboxazid which had unexpectedly high activity on the rat fundal strip preparation, and tranylcypromine which was devoid of tryptamine-potentiation action on the rat fundus preparation although it inhibited rat brain mono-amine oxidase in vitro and potentiated the action of tryptamine in vivo. Tranylcypromine was considerably less active in inhibiting the mono-amine oxidase of rat fundus than rat brain tissue in vitro, while iproniazid and isocarboxazid had about the same potency on the enzyme from the two tissues.

Animals↗

Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro.

The use of a sensitive enzymatic assay demonstrates that tryptamine occurs normally in rat brain. Intracisternal administration of [(14)C]tryptamine results in the formation of N-methyl-and dimethyltryptamine(a psychotomimetic compound)in the rat brain. An enzyme that converts tryptamine and N-methyl-tryptamine to N-methyl-and dimethyltryptamine was found to be present in rat and human brain. The N-methylation of tryptamine was inhibited by normally occurring compounds present in rat brain.

Animals↗

Synergic effects of tryptamine and octopamine on ophiuroid luminescence (Echinodermata).

In ophiuroids, bioluminescence is under nervous control. Previous studies have shown that acetylcholine is the main neurotransmitter triggering light emission in Amphipholis squamata and Amphiura filiformis. By contrast, none of the neurotransmitters tested so far induced luminescence in two other ophiuroid species, Ophiopsila aranea and Ophiopsila californica. The aim of this work was thus to investigate the putative involvement of two biogenic amines, tryptamine and octopamine, in light emission of three ophiuroid species. A. filiformis responds to both tryptamine and octopamine, mainly on its arm segments, while O. californica only responds to tryptamine stimulation. By contrast, tryptamine and octopamine do not seem to be involved in O. aranea luminescence control since none of these substances induced light emission in this species. The synergic effects of several other drugs with tryptamine and octopamine were also tested.

Analysis of Variance↗

Effect of phospholipase A2 on temperature-induced high-affinity [3H]tryptamine binding sites in rat brain.

To investigate a link between membrane phospholipids and tryptamine binding molecules, we examined the effects of phospholipases A2 and D on the temperature-sensitive high-affinity [3H]tryptamine binding sites in rat brain. When the phospholipase A2-treated membranes were exposed to 1% bovine serum albumin (BSA) before assaying for [3H]tryptamine binding, a complete dose-dependent inhibition curve was observed. At a concentration of 0.03 U, the action of phospholipase A2 resulted in the splitting of phosphatidylserine (PS), choline phosphatides (PC) and ethanolamine phosphatides (PE) by about 32, 34 and 65%, respectively, and reduced [3H]ligand binding by about 32%. On the contrary, in the case of phospholipase D (500 U), PS and PC decreased by about 8% and 33% and PE by about 29% with no significant alteration in the binding capacity. Moreover, Scatchard analysis of the [3H]tryptamine binding showed that phospholipase A2 drastically increased only the KD value of the high affinity sites, and this was accompanied by a decrement of the Bmax values of both the high and low affinity binding sites. From these results, it is inferred that certain lipids (PS) may be a modulator for the function of the temperature-induced high-affinity [3H]tryptamine binding molecules.

Animals↗

Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.

The functional significance of the interaction between serotonergic and dopaminergic neurotransmission is still uncertain. To document this interaction further, specific behavioral responses of rats to tryptamine and apomorphine were studied. The sequential injection of these agonists, at time intervals with minimal direct behavioral interference, was used to observe response changes with respect to a single challenge. The antagonists haloperidol, ritanserin and risperidone, with known actions on serotonin-S2 (5-HT2) and dopamine-D2 (D2) receptors were used to evaluate effective antagonism of single and sequential challenges. When tryptamine was preceded by an apomorphine challenge the effective doses of the 5-HT2 antagonists ritanserin and risperidone for 50% inhibition of the seizures increased by a factor of 2.5. The dose-response curve of haloperidol remained virtually unchanged, apparently because of the potent dopamine-D2 antagonism associated with these doses which may block the potentiating effect of apomorphine. When apomorphine was preceded by a tryptamine challenge, the total agitation score of the control animals increased by 59% on the average. Haloperidol was equally effective against the enhanced as against the unenhanced apomorphine response. Ritanserin reduced agitation only by the part corresponding to the tryptamine enhancement. Risperidone's activity against the enhanced agitation started at very low doses and was complete at a dose still about 2.5 times lower than that required against the single apomorphine challenge. Mutual enhancement of tryptamine and apomorphine appears to occur even at a time when the behavioral effects of the first agonist are no longer manifest. The enhanced agitation remains largely dopamine-D2-specific and the enhanced seizures serotonin 5-HT2-specific.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

[Change in tryptamine metabolism in vitamin B12 deficiency].

The metabolism of tryptamine was studied in rats in health and in vitamin B12 deficiency. Excretion of cobalamin with urine before and after loading with tryptamine was studied. Daily excretion of tryptamine with urine in vitamin B12-deficient animals was normal or slightly increased. At the same time, the increase in tryptamine excretion with urine in response to tryptophan administration was 2-fold lower in vitamin B12-deficient rats as compared with controls. These data may be interpreted to occur due to a decrease in the rate of tryptamine metabolism in vitamin B12 deficiency in rats. Impairments in metabolism of biogenic amines appear to be involved in the development of neuro-mental diseases accompanied by vitamin B12 deficiency.

Animals↗

Effects of pargyline, reserpine and neurotoxin lesions on [3H]tryptamine binding sites in rat brain.

[3H]Tryptamine binding sites were measured in 4 areas of rat brain following treatment with either pargyline or reserpine for 12 days, or 5 days and 30 days following intraventricular injections of 6-hydroxydopamine or 5,7-dihydroxytryptamine. Pargyline treatment decreased [3H]tryptamine binding in cerebral cortex, hippocampus, striatum and hypothalamus. Reserpine treatment increased binding in the cerebral cortex and hippocampus, but not in the striatum or hypothalamus. Neither 6-hydroxydopamine nor 5,7-dihydroxytryptamine altered [3H]tryptamine binding in any of the 4 brain areas. These results indicate that [3H]tryptamine binding sites in brain may be modified by drugs that can potentially affect tryptamine metabolism, and that the sites are not located on catecholamine or serotonin axons.

Animals↗